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Abstract
Background: Thrombotic microangiopathies (TMA) in adults such as thrombotic thrombocytopenic purpura (TTP) and
hemolytic uremic syndrome (HUS) are life-threatening disorders if untreated. Clinical presentation is highly variable and
prognostic factors for clinical course and outcome are not well established.
Methods: We performed a retrospective observational study of 62 patients with TMA, 22 males and 40 females aged 16 to
76 years, treated with plasma exchange at one center to identify clinical risk factors for the development of renal
insufficiency.
Results: On admission, 39 of 62 patients (63%) had acute renal failure (ARF) with 32 patients (52%) requiring dialysis
treatment. High systolic arterial pressure (SAP, p=0.009) or mean arterial pressure (MAP, p=0.027) on admission was
associated with acute renal failure. Patients with SAP.140 mmHg on admission had a sevenfold increased risk of severe
kidney disease (OR 7.464, CI 2.097–26.565). MAP.100 mmHg indicated a fourfold increased risk for acute renal failure (OR
4.261, CI 1.400–12.972). High SAP, diastolic arterial pressure (DAP), and MAP on admission were also independent risk
factors for persistent renal insufficiency with the strongest correlation for high MAP. Moreover, a high C-reactive protein
(CRP) level on admission correlated with renal failure in the course of the disease (p=0.003). At discharge, renal function in
11 of 39 patients (28%) had fully recovered, 14 patients (23%) remained on dialysis, and 14 patients (23%) had non-dialysis-
dependent chronic kidney disease. Seven patients (11%) died. We identified an older age as risk factor for death.
Conclusions: High blood pressure as well as high CRP serum levels on admission are associated with renal insufficiency in
TMA. High blood pressure on admission is also a strong predictor of sustained renal insufficiency. Thus, adult TMA patients
with high blood pressure may require special attention to prevent persistent renal failure.
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Introduction
Thrombotic microangiopathies (TMA) such as HUS or TTP
are rare microangiopathic thrombotic disorders characterized by
hyaline thrombi in the arterial microvasculature, Coombs-negative
hemolytic anemia, and thrombocytopenia. Prior to the introduc-
tion of plasma infusion and plasma exchange therapy, TMA was
associated with a mortality rate of more than 90% in adults [1,2].
In recent years, with the advent of plasma exchange in TMA
mortality rate could be drastically decreased, but TMA can still be
viewed as a life-threatening disorder with the outcome depending
on the underlying disease, the age of the patient, severity of organ
damage (e.g. kidney, heart, brain), and on the time lapse between
the onset of symptoms and initiation of plasma therapy.
A variety of possible triggers such as gastrointestinal infection
with E.coli O157:H7, E.coli O104:H4 or Shigella for typical HUS and
genitourinary or respiratory infections, human immunodeficiency
virus infection, hormonal dysbalance, drugs, tumours, inherited
and acquired defects in complement components and autoim-
mune diseases for TTP and adult atypical HUS have been
identified [3,4,5]. However, in up to 30% of cases the underlying
cause remains unclear. Recently, a large outbreak of E.coli
O104:H4 in Germany demonstrated the clinical severity of this
disease [6]. New pathophysiological approaches identified a low
activity of ADAMTS13, a metalloprotease responsible for cleavage
of unusually large von Willebrand factor (ULvWF) multimers, to be
responsible for TTP development [3,7,8]. However, according to
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in only 15% of patients with TMA [9], suggesting the presence of
additional unrecognized risk factors predisposing for the onset and
clinical course of TMA. Patients with atypical HUS may have a
deficiency of complement factor H or auto-antibodies directed
against this protein. Furthermore, mutations in the membrane
cofactor protein gene (MCP/CD46), in the complement factor I
gene, in the complement factor B gene or in the thrombomodulin
gene may also be present [10,11,12]. In atypical HUS and selected
Shiga-toxin-induced HUS cases the humanized monoclonal anti-
C5 antibody eculizumab was reported to be beneficial [13,14,15].
In contrast to HUS patients, classic TTP patients usually present
with predominant neurological symptoms. Since there is consid-
erable clinical overlap between these two entities the disease is
often referred to as HUS/TTP [16].
Presently, there is a need for risk stratification to guide therapy
and follow-up. Therefore, we analysed 62 consecutive adult
patients with TMA admitted to our hospital between 1989 and
2006.
Methods
Study design
The aim of this study was to identify clinical risk factors for acute
renal failure, persistent renal insufficiency and for mortality in adult
TMA patients. Data of 62 patients (22 males, 40 females)
consecutively admitted to our hospital between June 1989 and
June 2006attheageof16to76yearswiththeirfirstepisodeofacute
TMA were analyzed. This study was reviewed and approved by the
Institutional Review Board of Du ¨sseldorf University as exempt
research without requirement for informed consent as this was
review of existing data. TMA was diagnosed on the basis of clinical
criteria: thrombocytopenia of less than 100,000/ml, Coombs-
negative hemolytic anemia (Hb,12 g/dl, LDH.240 U/l), and
the presence of more than two schistocytes per visual field in the
peripheral blood smear. Other causes of severe thrombocytopenia,
in particular disseminated intravascular coagulation or idiopathic
thrombocytopenic purpura, were excluded. Almost all patients in
this study were treated with plasmapheresis. 57 of the patients
underwent plasma exchange therapy within 12 hours after
admission; three patients received plasma infusion due to less
severe disease. Two patients died from severe cerebral hemorrhage
before initiation of plasma therapy. Medical records of all patients
were examined for clinical signs of TMA and potential risk factors
for the disease. In this study, we did not classify patients into TTP,
HUS, or overlap syndromes by determining ADAMTS13 levels,
factor H, B, I, MCP or thrombomodulin gene mutations [11,12,17]
because these data were only available in a subset of patients.
Furthermore, although the concept of ADAMTS13 deficiency or
mutations in complement factors being responsible for the
development of TMA is important, TMA patients still represent a
very heterogenous group. Thus, the known pathophysiologic
approaches are applicable to some, but not all TMA patients
[9,12,18,19,20].
Clinical parameters (age, sex, SAP, DAP, MAP, white blood cell
count, hemoglobin concentration, platelet count, LDH, serum
creatinine, blood urea nitrogen (BUN), CRP) were analysed on
admission and at discharge. For plasmapheresis, we routinely
administered 250 mg methylprednisolone i.v. per day initially for
the first three days followed by 1–4 mg/kg body weight of
prednisone orally per day, usually at the same time as plasma
therapy.
Acute renal failure (ARF) in patients with no prior history of
kidney disease was defined by an increase of serum creatinine
levels of .0.5 mg/dl in 48 hours. In patients with renal
insufficiency (baseline creatinine $1.5 mg/dl) ARF was defined
by a rise in serum creatinine of $1 mg/dl from baseline over a
period of 48 hours. Patients with elevated serum creatinine
$1.5 mg/dl at discharge were categorized to have persistent
renal insufficiency. All patients were treated on the intensive care
unit (ICU) until platelet levels rose to more than 50 000/ml.
Symptomatic treatment consisted of blood pressure control,
electrolyte and water balance control, and whole blood transfu-
sions if necessary.
‘‘Remission’’ was defined as normalization of serum creatinine
#1.2 mg/dl and reversal of neurological symptoms. All patients
categorized as remission did not exhibit proteinuria at the time of
discharge. Systolic blood pressure was normalized in 9 of 11
patients with renal insufficiency on admission and remission at
discharge. Diastolic blood pressure was normalized in all these
patients.
Statistical Analysis
The objective of this study was (1) to analyse potential
differences between patients with renal impairment and patients
with normal renal function on admission, (2) to find potential risk
factors for persistent renal insufficiency and (3) to find potential
risk factors for mortality. For this purpose we used the non-
parametric Mann-Whitney test and performed pairwise compar-
isons for the baseline factors CRP, blood pressure, platelets, LDH
and white blood cell count (WBC). Additionally, SAP and MAP
were defined with 140 and 100 mmHg as cut-off, and odds ratios
(OR) and their 95% confidence intervals (CI) were assessed to
describe the strength of association between these factors and the
renal status on admission (situation 1).
For persistent renal insufficiency, the prognostic impacts of the
baseline factors were first explored one at a time by logistic
regression analyses, adjusted for renal status on admission. Factors
associated with a p value of the Wald type ,20% were examined
more closely in a multivariate logistic regression model, using
forward selection. Results are expressed as OR with their 95% CI.
The variables CRP, WBC, platelets and LDH were natural
logarithm transformed for inclusion in regression analyses
(situation 2).
In situation 3, we analysed additionally to the parameters from
situation 1 and 2 the factors age, haemoglobin, schistocytes and
creatinine. Due to small sample sizes, a logistic regression analysis
was not feasible, thus we used a non-parametric Mann Whitney
test and performed pairwise comparisons for surviving and
deceased patients.
If not stated otherwise, continuous variables were presented as
median (interquartile range (IQR)), categorical variables were
presented as proportions (%). Because of the explorative character
of this study we did not adjust the significance level a=0.05 to
account for multiple testing. Therefore, all p-values are of an
explorative nature and p values,0.05 were considered to be
statistically significant. All reported p-values are two-sided. The
analyses were performed using PASW Statistics 18.0.3 for
Windows (SPSS 2010, Chicago, Il., USA).
Results
Clinical characteristics of patients on initial presentation
62 consecutive patients diagnosed with adult TMA were
analysed in this study (table 1). Median age at presentation was
35 years with a wide range of 16 to 76 years (interquartile range
(IQR): 27–49). Two thirds of our patients were female. 82% of
patients only had a single episode of TMA whereas 18% relapsed
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neurological impairment varying from less severe symptoms such
as headache and dizziness to severe seizures and coma. Renal
insufficiency at presentation was very common (table 1). Most of
our patients had no history of renal insufficiency prior to their first
TMA episode. In patients with history of chronic renal failure, 3
patients had received a renal transplant, 2 patients had SLE, and
one patient had scleroderma.
The different underlying causes of TMA in our patients are
summarized in table 1. 31% of all patients had no obvious clinical
trigger for the development of TMA.
19% of our patients were known to suffer from hypertension
prior to the onset of TMA, whereas 81% did not show any medical
history of hypertension.
Clinical outcome
At discharge, remission (no renal insufficiency, no proteinuria,
no neurological symptoms) was achieved in 42% of patients
(table 2). Renal failure had resolved in 11 of 39 patients. The
number of dialysis-dependent patients decreased from 52% to
23% (table 2). Only two patients, one with renal insufficiency on
admission and one without, still had a neurological deficit at
discharge. Among those patients with no previous hypertension,
32% required antihypertensive treatment at the time of discharge.
7 patients with TMA died (table 2), one of sepsis, three of
severe cerebral hemorrhage, and three of TMA-associated
acute myocardial infarction where immediate lysis therapy was
unsuccessful.
Clinical markers for renal insufficiency on admission
C-reactive protein (CRP) levels on admission were significantly
higher in patients with renal insufficiency compared to patients
with normal renal function (table 3, figure 1). Taking the median
of CRP values (2.7 mg/dl) to divide patients into two subgroups,
10 patients with CRP$2.7 mg/dl had infections whereas 20
patients did not have signs of infection (6 patients with unknown
trigger of TMA, 5 patients post-partum, 3 patients with tumour, 3
patients with drug-induced TMA, 2 patients with SLE).
Blood pressure levels, MAP and SAP, were also significantly
higher in patients with renal impairment on admission (table 3,
figure 1). Patients with SAP.140 mmHg on admission had a
sevenfold increased probability of renal insufficiency on admission
(odds ratio (OR) 7.464, CI 2.097–26.565). Patients with
MAP.100 mmHg on admission had a fourfold increased
probability (OR 4.261, CI 1.400–12.972) of acute renal insuffi-
ciency. There was a tendency for lower DAP in patients with
normal renal function. Platelet count was significantly lower in
patients with normal renal function (Table 3). This finding reflects
the high proportion of patients with a clinical diagnosis of TTP in
this group who often present with very low thrombocyte counts
but with normal renal function. No significant difference was
observed for LDH levels or white blood cell count (WBC), as
described previously [21].
In our study, schistocytes remained elevated in some patients
although LDH levels and platelet count were already normalized
(data not shown). Therefore, as published earlier [22], schistocytes
were unreliable markers for the detection of disease activity.
Table 1. Clinical characteristics of patients on admission.
n (%) Median (IQR)
Associated risk factors for the
development of TMA n (%)
Total number of patients 62 Infection 18 (29.0)
Age at first event (yr) 35 (27–49) Pulmonary infection 5 (8.1)
Female gender 40 (64.5) Diarrhea 7 (11.3)
Male gender 22 (35.5) Pregnancy / oral contraceptives 8 (12.9)/2 (3.2)
Patients with single event 51 (82.3) Renal transplantation 4 (6.5)
Patients with relapsing TMA 11 (17.7) Malignancy 4 (6.5)
Neurological symptoms 32 (51.6) SLE 3 (4.8)
Renal impairment 39 (62.9) Systemic sclerosis 2 (3.2)
Dialysis treatment 32 (51.6) Drugs 2 (3.2)
Unknown 19 (30.6)
IQR: Interquartile range.
doi:10.1371/journal.pone.0030886.t001
Table 2. Clinical outcome.
All patients
n (%)
Renal impairment on admission
n (%)
Normal renal function on admission (n=23)
n (%)
Remission 26 (41.9) 8 (20.5) 18 (78.3)
Renal insufficiency without dialysis 14 (22.6) 10 (25.6) 2 (8.7)
Dialysis 14 (22.6) 11 (28.2) 0 (0)
Neurological deficit 2 (3.2) 1 (2.6) 1 (4.3)
Death 7 (11.3) 5 (12.8) 2 (8.7)
doi:10.1371/journal.pone.0030886.t002
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Our objective of this study was to identify clinical markers to
detect patients at risk for TMA-induced sustained renal insuffi-
ciency. We performed logistic regression analyses, adjusted for
renal status on admission (table 4), comparing patients on
admission and at discharge. Potential risk factors influencing renal
status at discharge were high MAP, SAP, DAP, and LDH levels on
admission (table 4). We observed a strong association of elevated
MAP on admission with renal insufficiency at discharge in
multivariate analysis (table 5). An increase in MAP by 10 mmHg
was associated with a twofold increased chance for renal
insufficiency at discharge. This finding indicates that patients with
renal dysfunction on admission as well as at discharge have higher
blood pressure levels compared to patients with normal renal
function.
In our logistic regression analysis (table 4), LDH levels were
higher in patients with renal impairment on admission and at
discharge compared to patients with normal renal function.
Risk factors for death from TMA
The only associated risk factor for death in our study population
was older age (table 6). MAP, SAP, DAP, LDH levels, CRP levels,
WBC,haemoglobin levels, thrombocyte counts, schistocyte levels or
creatinine levels were not significantly different in patients who died
from TMA compared to surviving patients. Multivariate analysis
was not performed due to the small number of deceased patients.
Figure 1. Risk factors for renal insufficiency in TMA. A: CRP serum levels on admission are significantly higher in patients with renal
insufficiency compared to patients with normal renal function. B: Systolic arterial pressure (SAP) and mean arterial pressure (MAP) on admission are
significantly higher in TMA patients with renal insufficiency.
doi:10.1371/journal.pone.0030886.g001
Table 3. Characteristic factors for acute renal failure on admission.
All patients (n=62)
Median (IQR)
Renal impairment (n=39)
Median (IQR)
Normal renal function
(n=23)
Median (IQR)
p-value
(Mann-Whitney-U test)
MAP (mmHg) 106 (90–117) 110 (95–120) 97 (87–110) 0.027*
SAP (mmHg) 140 (120–150) 150 (130–160) 130 (120–140) 0.009*
DAP (mmHg) 85 (70–100) 89 (80–100) 80 (70–90) 0.067
CRP (mg/dl) 2.7 (0.9–5.4) 2.9 (1.4–8.7) 0.95 (0.3–2.8) 0.003*
Platelets (/ml) 25 000 (9 000–56 000) 40 000 (18 000–85 000) 9 000 (8 000–26 000) 0.001*
LDH (U/l) 1 259 (714–2 001) 1 430 (765–2 799) 1 002 (630–1 650) 0.147
WBC (/ml) 10 800 (7 000–13 500) 11 900 (7 100–15 600) 9 400 (6 200–12 000) 0.062
*values significantly higher in patients with impaired renal function compared to patients with normal renal function on admission (p,0.05). IQR: Interquartile range.
doi:10.1371/journal.pone.0030886.t003
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TMA is a life-threatening disease that was previously associated
with a high mortality of more than 90% before plasmapheresis was
introduced as therapy for TMA patients. Nowadays, survival rates
have significantly improved, but sporadic non-Shiga-toxin-in-
duced HUS still has a mortality rate of up to 50% in some patient
subgroups [17]. The 2011 outbreak of E.coli O104:H4 in Germany
demonstrated the severity of this disease very clearly, where at least
27 patients died from diarrhea-associated HUS [6].
This study was designed to evaluate clinical risk factors
predisposing TMA patients to renal insufficiency. The clinical
course of a single patient presenting with TMA is often difficult to
predict. Therefore, we analyzed data of 62 consecutively treated
TMA patients to identify markers for the development of renal
insufficiency and for the lack of renal recovery after successful
TMA treatment.
Attempts to clinically define prognostic factors for the
development of renal insufficiency in TMA have already been
made earlier [21,23,24,25]. Hollenbeck and co-workers demon-
strated the importance of plasmapheresis to prevent the
development of end-stage renal disease compared to plasma
infusion alone [21]. In three studies pre-existing nephropathy or
severe renal involvement were identified as risk factors for
chronic renal failure [23,24,25]. Four studies correlated chronic
renal failure to the severity of arterial and glomerular damage on
renal biopsy [23,24,25], whereas one study did not find any
correlation between renal histology and renal prognosis [21].
Compared to the present analysis patient subgroups were
different. In the study by Hollenbeck et al. only 71% of patients
were treated with plasmapheresis. Tostivint and colleagues
reported exclusively on HUS patients, not on TTP patients,
mostly treated with plasma infusion [23], with a large cohort of
HIV positive cases. In our study patients were treated almost
exclusively with plasmapheresis.
Acute renal failure (ARF) in TMA patients is frequently seen.
In our study, more than 60% of patients showed renal
impairment at presentation confirming results that have been
published earlier (for review, see [17],[26],[27]). We identified
high CRP and high blood pressure as clinical markers associated
with ARF in TMA patients. CRP serum levels on admission
were significantly increased in patients with ARF compared to
patients with normal renal function. Therefore, high CRP may
serve as a risk factor for ARF in TMA. CRP is a non-specific
acute phase protein synthesized and degraded in the liver. It is
markedly elevated in septic states in which ARF develops with a
prevalence of 9–40% [28]. In our study, sepsis only played a
minor role as a potential cause of ARF. The reason for high
CRP levels in our patient subgroup with ARF is unclear. They
usually occur in response to infection and inflammation. In the
renal insufficiency group they may reflect additional, clinically
undetected infection, possibly facilitating the development of
ARF. Since WBC was not elevated in patients with higher CRP
levels it is unlikely that severe infections were the reason for CRP
elevation. Therefore, high CRP levels should rather be
interpreted as an indicator for the severity of TMA-induced
organ damage, including the kidney. Going along the same line
with our observation, a Japanese study on diarrhea-associated
typical HUS in children (D+ HUS) identified high CRP serum
levels as a risk factor for the development of severe CNS
disorders [29]. High CRP has also been recognized as a
prognostic indicator in chronic renal disease. [30,31]. Serum
CRP levels predict death in dialysis patients [32,33]. In severe
renal insufficiency, elevation of CRP is associated with a higher
Table 4. Risk factors for renal insufficiency at discharge. Logistic regression analyses, adjusted for renal status on admission.
Renal impairment on
admission only (n=8)
Median (IQR)
Renal impairment on
admission and at discharge
(n=26)
Median (IQR)
Normal renal function on
admission and at discharge
(n=19)
Median (IQR)
p-value
(Wald-Test)
MAP (mmHg) 96 (88–111) 113 (105–124) 93 (83–107) 0.011*
SAP (mmHg) 133 (120–148) 150 (139–173) 120 (110–140) 0.025*
DAP (mmHg) 80 (70–93) 90 (80–100) 80 (70–90) 0.023*
CRP (mg/dl) 2.75 (1.1–4.9) 2.9 (1.5–9.5) 1.1 (0.3–3.9) 0.816
LDH (U/l) 1 835 (1 038–3 655) 1 346 (670–2 001) 1 002 (630–1 650) 0.082*
WBC (/ml) 11 900 (6 600–13 900) 11 050 (7 000–16 300) 9 400 (6 100–12 000) 0.894
*values higher in patients with impaired renal function compared to patients with normal renal function at discharge (p,0.20). IQR: Interquartile range.
doi:10.1371/journal.pone.0030886.t004
Table 5. Risk factors for renal insufficiency at discharge, multivariate logistic regression analysis.
b
(a) SE
(b) p-value (Wald Test) Odds Ratio (95% CI)
Renal impairment on admission
(c) 3.290 0.927 ,0.001 26.84 (4.36–165.11)
MAP (mmHg) 0.070 0.028 0.011 1.07 (1.02–1.13)
Constant 212.869 3.630 ,0.001
(a)b, estimated regression coefficient,
(b)standard error of b,
(c)‘‘yes’’ coded 1.
doi:10.1371/journal.pone.0030886.t005
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endothelial damage and atherogenesis [34,35]. CRP might
therefore play an active role in endothelial damage also in
TMA patients, independently of its elevation in septic states.
Thus, high CRP levels may reflect TMA activity itself, leading to
more severe end-organ damage and ARF.
In our cohort, high blood pressure (MAP) in patients with renal
insufficiency on admission was a risk factor for acute and persistent
renal insufficiency. Tostivint and co-workers already indicated that
high DAP was associated with chronic renal failure but they did
not identify high DAP as independent risk factor in multivariate
analysis [23]. Higher blood pressure is either due to pre-existing
hypertension or due to secondary hypertension caused by TMA-
related renal involvement. Interestingly, only a minority of patients
was known to be hypertensive prior to their episode of TMA. Most
of our patients also did not have any previous history of kidney
disease. Our data suggest that adequate treatment of hypertension
in TMA patients may be essential to prevent additional renal
damage. By lowering blood pressure into the normal range renal
function might be preserved and may lead to a better renal
outcome.
LDH serum levels at the time of admission were higher in
patients with sustained renal insufficiency at discharge compared
to patients with normal renal function. This finding is not
surprising since LDH levels indicate the severity of hemolysis and
of end-organ damage. Higher LDH levels in patients with
persisting renal insufficiency suggest a more severe course of
TMA and presumably also more severe kidney damage.
Several risk factors for the development of TMA, such as
infection, pregnancy, autoimmune disease or drugs, have been
published. We found these to be present in 69% of our patients.
One third of patients did not show any apparent trigger. Genetic
testing of genes encoding complement factors and determination
of ADAMTS13 activity have been demonstrated to be useful to
clarify the etiology of TMA [12]. Recent studies show that 20%
of HUS patients have a familiar form of HUS [26], and 80% of
TTP is triggered by deficient activity of ADAMTS13 [12].
Unfortunately, these data were only available in a minority of our
patients.
11% of patients in our study died due to sepsis, hemorrhage,
and acute myocardial infarction. This mortality rate is compa-
rable to mortality rates previously published for this disorder
[17,25,36]. We identified older age as a risk factor for death
confirming results of Shiepatti and co-workers [24]. We did not
observe any association between risk of death and blood pressure,
CRP serum levels, LDH serum levels, Hb, WBC, thrombocytes,
schistocytes, or creatinine serum levels on admission. Data
published earlier suggested that low hemoglobin levels as well
as high WBC were also associated with a higher risk of death
[21]. In our study, we were not able to confirm these findings.
This may reflect differences between patient subgroups in both
studies.
For interpretation of this study some limitations should be taken
into account. The study took place in a single hospital with a
particular clientele of patients that might be different compared to
hospitals in other regions or other countries. For example, we did
not observe any HIV infections in our patient cohort. Further-
more, a single site investigation often presents data on only a
limited number of cases.
In summary, we were able to identify parameters significantly
correlated with unfavorable outcomes in TMA patients. High
CRP serum levels and high blood pressure indicate a predispo-
sition for ARF and persistent renal insufficiency. These parameters
could help to detect TMA patients at risk for sustained kidney
function impairment. Therapy of the underlying cause of CRP
elevation as well as immediate and sufficient lowering of blood
pressure may improve renal prognosis.
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Table 6. Risk factors for TMA-associated death.
Surviving patients
(n=55)
Median (IQR)
Deceased patients
(n=7)
Median (IQR) p-value
Age (yrs) 34 (26–45) 48 (41–65) 0.009 *
MAP (mmHg) 106 (93.33–116.67) 95 (90–106.67) 0.346
SAP (mmHg) 140 (120–150) 130 (120–150) 0.512
DAP (mmHg) 87 (70–100) 80 (70–85) 0.280
LDH (U/l) 1 241 (694–1 935) 1 430 (1 086–3 570) 0.171
CRP (mg/dl) 2.5 (0.9–4.4) 3.6 (2.2–8.7) 0.386
WBC (/ml) 10 600 (6 400–13 800) 12 600 (10 000–13 500) 0.182
Hemoglobin (g/dl) 8.2 (7.1–9.8) 7.7 (5.7–11.3) 0.730
Platelets (/ml) 26 000 (9 000–58 000) 12 000 (5 000–56 000) 0.344
Schistocytes per field of view 6 (3–9) 7 (7–8) 0.528
Creatinine (mg/dl) 2.5 (1–5.2) 1.5 (1–4.3) 0.815
IQR: Interquartile range.
doi:10.1371/journal.pone.0030886.t006
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